top of page
News, Events and Updates
Search
Oct 21, 2013
Anavex Encouraged by New Sigma-1 Receptor Study That May Explain Therapeutic Efficacy of ANAVEX 2-73
Sep 22, 2013
Anavex Comments on Newly Released World Alzheimer Report 2013
Sep 2, 2013
Anavex to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York
Aug 14, 2013
Anavex CEO Writes Letter to Shareholders
Jul 7, 2013
Anavex Raises $2.6M in Private Placement and Conversion of Liabilities, Enters into $10M Financing
May 5, 2013
Anavex Invited to File Funding Application for Phase 2a Clinical Trial of ANAVEX 2-73
Mar 17, 2013
Anavex Comments on FDA Plan to Expedite Approval of New Alzheimer's Drugs
Mar 11, 2013
ANAVEX 2-73 Restores Mitochondrial Functionality, Clocks Cell Death and Oxidative Stress
Mar 6, 2013
Mitochondrial Protection in Mouse Hippocampus against Aβ25-35 Toxicity is Induced by the Novel...
Feb 4, 2013
Anavex Retains Novak Druce Connolly Bove & Quigg; Maximize Value of Intellectual Property Portfolio
Jan 11, 2013
Amyloid Toxicity Induced by Oligomeric Aβ25-35 Injection Enhanced after Pharmacologic or Genetic...
40
41
42
43
44
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
